These results indicate the interest in nucleoside 10 as a promising lead compound for Alzheimer’s disease symptomatic treatment, allying its significant ability to inhibit BChE with its low in vitro neuro- and hepatotoxicity. Here, BCHE is linked to early-onset autosomal dominant Alzheimer disease.